Literature DB >> 15153470

A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL.

Michael A Lyman1, Sandra Aung, Judith A Biggs, Linda A Sherman.   

Abstract

In this report, we address whether a growing tumor provides sufficient inflammatory signals to promote activation, clonal expansion, and acquisition of effector functions by naive tumor-specific CD8(+) T lymphocytes. CD8(+) T lymphocytes obtained from hemagglutinin (HA)-specific clone 4 TCR-transgenic mice were injected into recipient mice that spontaneously develop pancreatic tumors expressing HA as a tumor-associated Ag (RIP-Tag2-HA mice). When 3 x 10(6) clone 4 CD8(+) T cells were transferred into tumor-bearing mice, the cells became activated in the pancreatic lymph nodes where they proliferated and acquired effector functions such as cytolytic activity and IFN-gamma production. Surprisingly, reducing the number of adoptively transferred CD8(+) T cells led to a parallel reduction in the proportion of the activated cells that exhibited effector functions, suggesting that CTL differentiation was induced by the large numbers of activated CD8(+) T cells and not the tumor environment. Provision of tumor-specific CD4(+) helper cells provided the signals required to promote both the development of CTL effector functions and increased clonal expansion, resulting in tumor eradication. Considering that only small numbers of tumor-specific CD8(+) T cells would be present in a conventional T cell repertoire, these data suggest that tumor growth alone may not provide the inflammatory signals necessary to support the development of CD8(+) T cell effector functions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153470     DOI: 10.4049/jimmunol.172.11.6558

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

2.  Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.

Authors:  Laura A Johnson; Bianca Heemskerk; Daniel J Powell; Cyrille J Cohen; Richard A Morgan; Mark E Dudley; Paul F Robbins; Steven A Rosenberg
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

3.  Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.

Authors:  Tullia C Bruno; Cristin Rothwell; Joseph F Grosso; Derese Getnet; Hung Rong Yen; Nicholas M Durham; George Netto; Drew M Pardoll; Charles G Drake
Journal:  Prostate       Date:  2011-07-14       Impact factor: 4.104

4.  Costimulation Induces CD4 T Cell Antitumor Immunity via an Innate-like Mechanism.

Authors:  Crystal Morales Del Valle; Joseph R Maxwell; Maria M Xu; Antoine Menoret; Payal Mittal; Naomi Tsurutani; Adam J Adler; Anthony T Vella
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

Review 5.  Prostate cancer as a model for tumour immunotherapy.

Authors:  Charles G Drake
Journal:  Nat Rev Immunol       Date:  2010-08       Impact factor: 53.106

6.  Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.

Authors:  Aaron M Miller; Milad Bahmanof; Dietmar Zehn; Ezra E W Cohen; Stephen P Schoenberger
Journal:  Cancer Immunol Res       Date:  2018-11-27       Impact factor: 11.151

Review 7.  Intravital imaging of CD8+ T cell function in cancer.

Authors:  Thorsten R Mempel; Christian A Bauer
Journal:  Clin Exp Metastasis       Date:  2008-07-30       Impact factor: 5.150

8.  Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses.

Authors:  Michael Y Gerner; Kerry A Casey; Matthew F Mescher
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  Tumor antigen cross-presentation and the dendritic cell: where it all begins?

Authors:  Alison M McDonnell; Bruce W S Robinson; Andrew J Currie
Journal:  Clin Dev Immunol       Date:  2010-10-13

10.  Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance.

Authors:  Yonghua Wang; Qianyuan Zhuang; Siwei Zhou; Zhiquan Hu; Ruzhu Lan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.